Learn More
D-501036 [2,5-bis(5-hydroxymethyl-2-selenienyl)-3-hydroxymethyl-N-methylpyrrole] is herein identified as a novel antineoplastic agent with a broad spectrum of antitumoral activity against several(More)
5514 Background: The ECOG conducted two successive phase III randomized trials comparing cisplatin-based doublets (E1393: cisplatin/paclitaxel, low dose vs. cisplatin/paclitaxel, high dose, and(More)
  • 1